Lack of Attention to the Administration of Fampridine as a Symptomatic Drug in Iranian Multiple Sclerosis Patients
2. LaRocca NG (2011). Impact of walking im-pairment in multiple sclerosis: perspec-tives of patients and care partners. Patient, 4:189–201
3. Van Asch P (2011). Impact of mobility im-pairment in multiple sclerosis 2-patients’ perspectives. European Neurological Review, 6(2):115-120.
4. Albrecht P, Bjørnå IK, Brassat D, et al (2018). Prolongedrelease fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting. Ther Adv Neurol Disord, 11:1756286418803248.
5. Sahraian MA, Sahebkar M, Dehghani R, et al (2017). Multiple sclerosis-A disease on a dramatically rising trend in Iran: Review of possible reasons. Iran J Neu-rol,16(1):34-40.
6. Anonymous (2018). The number of patients with MS in Iran. www.iranms.ir
7. Anonymous (2018). The Statistics of the Ministry of Health and Medical Educa-tion of the Islamic Republic of Iran. https://www.fda.gov.ir/
|Issue||Vol 50 No 7 (2021)|
|Section||Letter to the Editor|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|